CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.320
+0.150 (4.73%)
At close: Aug 4, 2026, 4:00 PM EDT
3.308
-0.012 (-0.36%)
Pre-market: Aug 5, 2026, 7:40 AM EDT
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $10.26M in the quarter ending March 31, 2026, a decrease of -79.85%. This brings the company's revenue in the last twelve months to $35.54M, down -75.91% year-over-year. In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%.
Revenue (ttm)
$35.54M
Revenue Growth
-75.91%
P/S Ratio
20.34
Revenue / Employee
$515,101
Employees
69
Market Cap
722.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76.20M | -61.90M | -44.82% |
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 299.77M |
| Phathom Pharmaceuticals | 239.66M |
| Gyre Therapeutics | 117.05M |
| Oculis Holding AG | 1.40M |
| Neurogene | 925.00K |
| Allogene Therapeutics | 22.00K |
CTMX News
- 1 day ago - CytomX Therapeutics appoints Alejandra Carvajal as chief legal officer - TheFly
- 2 days ago - CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - GlobeNewsWire
- 6 days ago - CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 - GlobeNewsWire
- 9 days ago - CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - GlobeNewsWire
- 7 weeks ago - CytomX Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - CytomX Therapeutics expands licensing agreement with Regeneron - TheFly
- 2 months ago - CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - GlobeNewsWire